Y-mAbs Therapeutics, Inc. (YMAB)
| Previous close | 14.91 |
| Open | 14.82 |
| Bid | 14.99 x 100 |
| Ask | 15.12 x 100 |
| Day's range | 14.65 - 15.69 |
| 52-week range | 4.60 - 20.90 |
| Volume | |
| Avg. volume | 395,451 |
| Market cap | 661.034M |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.49 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.43 |
ZacksWall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in YmAbs Therapeutics (YMAB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksYmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
GlobeNewswireY-mAbs Therapeutics Announces Resignation of Chief Financial Officer
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the Chief Fin
